BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 35522019)

  • 21. Dynamic evolution of imipenem/relebactam resistance in a KPC-producing Klebsiella pneumoniae from a single patient during ceftazidime/avibactam-based treatments.
    Gaibani P; Bovo F; Bussini L; Lazzarotto T; Amadesi S; Bartoletti M; Viale P; Ambretti S
    J Antimicrob Chemother; 2022 May; 77(6):1570-1577. PubMed ID: 35373297
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Resistance to ceftazidime-avibactam in a KPC-2-producing Klebsiella pneumoniae caused by the extended-spectrum beta-lactamase VEB-25.
    Findlay J; Poirel L; Bouvier M; Gaia V; Nordmann P
    Eur J Clin Microbiol Infect Dis; 2023 May; 42(5):639-644. PubMed ID: 36877262
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Monitoring Ceftazidime-Avibactam and Aztreonam Concentrations in the Treatment of a Bloodstream Infection Caused by a Multidrug-Resistant Enterobacter sp. Carrying Both Klebsiella pneumoniae Carbapenemase-4 and New Delhi Metallo-β-Lactamase-1.
    Yasmin M; Fouts DE; Jacobs MR; Haydar H; Marshall SH; White R; D'Souza R; Lodise TP; Rhoads DD; Hujer AM; Rojas LJ; Hoyen C; Perez F; Edwards A; Bonomo RA
    Clin Infect Dis; 2020 Aug; 71(4):1095-1098. PubMed ID: 31802119
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Successful ceftazidime-avibactam treatment of MDR-KPC-positive Klebsiella pneumoniae infection in a patient with traumatic brain injury: A case report.
    Gugliandolo A; Caio C; Mezzatesta ML; Rifici C; Bramanti P; Stefani S; Mazzon E
    Medicine (Baltimore); 2017 Aug; 96(31):e7664. PubMed ID: 28767588
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Identification of a KPC Variant Conferring Resistance to Ceftazidime-Avibactam from ST11 Carbapenem-Resistant
    Wu Y; Yang X; Liu C; Zhang Y; Cheung YC; Wai Chi Chan E; Chen S; Zhang R
    Microbiol Spectr; 2022 Apr; 10(2):e0265521. PubMed ID: 35416703
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Increased Expression and Amplification of
    Li X; Zhang J; Yang C; Li J; Wang J; Huang W; Zeng L; Liang X; Long W; Zhang X
    Microbiol Spectr; 2022 Aug; 10(4):e0095522. PubMed ID: 35900090
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The Effect of β-Lactam Antibiotics on the Evolution of Ceftazidime/Avibactam and Cefiderocol Resistance in KPC-Producing Klebsiella pneumoniae.
    Zhang P; Hu H; Shi Q; Sun L; Wu X; Hua X; McNally A; Jiang Y; Yu Y; Du X
    Antimicrob Agents Chemother; 2023 Mar; 67(3):e0127922. PubMed ID: 36794957
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy of ceftazidime-avibactam in various combinations for the treatment of experimental osteomyelitis due to Klebsiella pneumoniae carbapenemase (KPC)-producing Klebsiella pneumoniae.
    Davido B; Crémieux AC; Vaugier I; Gatin L; Noussair L; Massias L; Laurent F; Saleh-Mghir A
    Int J Antimicrob Agents; 2023 Jan; 61(1):106702. PubMed ID: 36476965
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy of Ceftazidime-Avibactam Salvage Therapy in Patients With Infections Caused by Klebsiella pneumoniae Carbapenemase-producing K. pneumoniae.
    Tumbarello M; Trecarichi EM; Corona A; De Rosa FG; Bassetti M; Mussini C; Menichetti F; Viscoli C; Campoli C; Venditti M; De Gasperi A; Mularoni A; Tascini C; Parruti G; Pallotto C; Sica S; Concia E; Cultrera R; De Pascale G; Capone A; Antinori S; Corcione S; Righi E; Losito AR; Digaetano M; Amadori F; Giacobbe DR; Ceccarelli G; Mazza E; Raffaelli F; Spanu T; Cauda R; Viale P
    Clin Infect Dis; 2019 Jan; 68(3):355-364. PubMed ID: 29893802
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prevalence and mortality of ceftazidime/avibactam-resistant KPC-producing Klebsiella pneumoniae bloodstream infections (2018-2022).
    Boattini M; Bianco G; Bastos P; Comini S; Corcione S; Almeida A; Costa C; De Rosa FG; Cavallo R
    Eur J Clin Microbiol Infect Dis; 2024 Jan; 43(1):155-166. PubMed ID: 37985552
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Genomic characterization of a KPC-23-producing Klebsiella pneumoniae ST258 clinical isolate resistant to ceftazidime-avibactam.
    Galani I; Antoniadou A; Karaiskos I; Kontopoulou K; Giamarellou H; Souli M
    Clin Microbiol Infect; 2019 Jun; 25(6):763.e5-763.e8. PubMed ID: 30928562
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Antimicrobial Activity of Ceftazidime-Avibactam against Gram-Negative Bacteria Isolated from Patients Hospitalized with Pneumonia in U.S. Medical Centers, 2011 to 2015.
    Sader HS; Castanheira M; Flamm RK
    Antimicrob Agents Chemother; 2017 Apr; 61(4):. PubMed ID: 28069649
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Molecular Mechanisms Driving the
    Li X; Ke H; Wu W; Tu Y; Zhou H; Yu Y
    mSphere; 2021 Dec; 6(6):e0085921. PubMed ID: 34935448
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Optimal ceftazidime/avibactam dosing exposure against KPC-producing Klebsiella pneumoniae.
    Tam VH; Merlau PR; Hudson CS; Kline EG; Eales BM; Smith J; Sofjan AK; Shields RK
    J Antimicrob Chemother; 2022 Oct; 77(11):3130-3137. PubMed ID: 36031868
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A Ceftazidime-Avibactam-Resistant and Carbapenem-Susceptible Klebsiella pneumoniae Strain Harboring
    Niu S; Chavda KD; Wei J; Zou C; Marshall SH; Dhawan P; Wang D; Bonomo RA; Kreiswirth BN; Chen L
    mSphere; 2020 Aug; 5(4):. PubMed ID: 32848008
    [TBL] [Abstract][Full Text] [Related]  

  • 36. In vivo evolution of resistant subpopulations of KPC-producing Klebsiella pneumoniae during ceftazidime/avibactam treatment.
    Gaibani P; Campoli C; Lewis RE; Volpe SL; Scaltriti E; Giannella M; Pongolini S; Berlingeri A; Cristini F; Bartoletti M; Tedeschi S; Ambretti S
    J Antimicrob Chemother; 2018 Jun; 73(6):1525-1529. PubMed ID: 29566151
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Emergence of ceftazidime/avibactam resistance in KPC-3-producing Klebsiella pneumoniae in vivo.
    Göttig S; Frank D; Mungo E; Nolte A; Hogardt M; Besier S; Wichelhaus TA
    J Antimicrob Chemother; 2019 Nov; 74(11):3211-3216. PubMed ID: 31365094
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Successive Emergence of Ceftazidime-Avibactam Resistance through Distinct Genomic Adaptations in
    Giddins MJ; Macesic N; Annavajhala MK; Stump S; Khan S; McConville TH; Mehta M; Gomez-Simmonds A; Uhlemann AC
    Antimicrob Agents Chemother; 2018 Mar; 62(3):. PubMed ID: 29263067
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Evaluation of the synergistic effect of eravacycline and tigecycline against carbapenemase-producing carbapenem-resistant Klebsiella pneumoniae.
    Huang YS; Yang JL; Wang JT; Sheng WH; Yang CJ; Chuang YC; Chang SC
    J Infect Public Health; 2024 May; 17(5):929-937. PubMed ID: 38599013
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparison of Four Carbapenemase Detection Methods for
    Ding L; Shi Q; Han R; Yin D; Wu S; Yang Y; Guo Y; Zhu D; Hu F
    Microbiol Spectr; 2021 Dec; 9(3):e0095421. PubMed ID: 34935416
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.